Session Abstract – PMWC 2022 Silicon Valley
The PMWC 2022 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).
Confirmed Presenting Companies:
Chris Hibberd has more than 20 years of diagnostics and biopharmaceutical experience in company formation, clinical and business development and commercialization. Prior to taking the helm of Nucleix, he was CEO and co-founder of Astute Medical. He managed a team and secured funding to support a product pipeline that included the launch of NephroCheck®, the first FDA cleared diagnostic for acute kidney injury risk, until its acquisition by bioMérieux. Prior to Astute Medical, he was SVP of corporate development at Biosite, where he managed business development activities that included cofounding Biosite Discovery, a world-class antibody capabilities collaboration, and Biosite’s $1.7 billion acquisition by Inverness Medical. Prior to that, he was a manager at The Boston Consulting Group and a development engineer at Albright & Wilson Americas. He obtained an MBA from the University of Western Ontario and a B.A.Sc. in chemical engineering from the University of Toronto.
Liquid Biopsy Showcase:
Nucleix is revolutionizing cancer treatment by leveraging its highly sensitive PCR and NGS-based EpiCheck® platform to find crucial markers and develop cost-effective screening tests for bladder and lung cancers – helping detect cancer earlier and potentially provide long-term benefit for patients.
EpiCheck®, Cancer Detection At The Earliest Moment
Sensitivity is crucial for early cancer detection. In this talk, Nucleix will outline how it leverages its highly sensitive PCR and NGS-based platforms to find the most important markers and then develop cost-effective PCR-based cancer screening tests for bladder and lung cancers. Highly sensitive tests in cancers like Lung Cancer have the potential to increase screening compliance and drive more patients to treatment when it has the greatest chance of providing long-term benefit.
JP leads R&D for Biological Dynamics’ proprietary Verita™ isolation platform, which enables the use of extracellular vesicle (EV)-based protein biomarkers for early cancer detection, as well as neurodegenerative and infectious diseases. His team is at the forefront of EV-based liquid biopsy technology, including the discovery of new applications and biomarkers enabled by AC Electrokinetics (ACE). He has been instrumental in developing Biological Dynamics’ technology demonstrating the capability of ACE to identify cell-free biomarkers. His most recent publication showcases how EV-protein markers can be used to detect stage I and stage II pancreatic, ovarian, and bladder cancers. Prior to joining Biological Dynamics, JP completed postdoctoral assignments for the United States Department of Energy’s Oak Ridge National Laboratory and the École Polytechnique Fédérale de Lausanne in Switzerland. JP has authored numerous publications in the fields of biocompatible, functional surfaces. He holds a PhD in Chemical & Biomolecular Engineering from Clemson University.
Liquid Biopsy Showcase:
Biological Dynamics, Inc. is a healthcare company committed to improving global health outcomes by detecting diseases at their earliest stages. The company's proprietary platform simplifies access to native-state biomarkers and nanoparticles, enabling differentiated multiomics applications.
Exosome Classifier For Early-Stage Cancer Detection
Biological Dynamics is advancing early cancer detection by leveraging its Verita™ platform to capture and analyze exosomes from early-stage (I/II) cancer patient samples. Analysis of exosomal biomarkers enables highly sensitive and specific cancer detection, potentially allowing earlier cancer intervention.